Quick Summary:
In the continuously expanding healthcare sector, the global market for Alpha 1 Antitrypsin Deficiency Treatment is projected to burgeon to an impressive size of US$3.8 Billion by 2030, making it a significant investment opportunity. This marked increase, from an estimated US$1.9 Billion in 2022, underlines the rapid development and adoption of various treatment options, including Augmentation Therapy and Bronchodilator treatments.
Possessing a foothold in this market space positions you competitively amidst pandemic recovery. Further, it allows you to leverage growth and expansion opportunities across different geographic borders. Having an acute understanding of the market, U.S, China, Japan, Canada, and Europe are seeing rapid progress, opening avenues for investments and collaborations. This report delineates the global competitiveness, potential market shares and presences across multiple geographies. With bespoke professional updates, online peer-to-peer collaborative assessments, you also gain access to digital archives and the publisher's Research Platform, with complimentary updates for a year, ensuring you stay on the top of the game.
Global Alpha 1 Antitrypsin Deficiency Treatment Market to Reach $3.8 Billion by 2030
The global market for Alpha 1 Antitrypsin Deficiency Treatment estimated at US$1.9 Billion in the year 2022, is projected to reach a revised size of US$3.8 Billion by 2030, growing at a CAGR of 9% over the analysis period 2022-2030. Augmentation Therapy, one of the segments analyzed in the report, is projected to record 9.7% CAGR and reach US$1.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Bronchodilator segment is readjusted to a revised 9.5% CAGR for the next 8-year period.The U.S. Market is Estimated at $575.4 Million, While China is Forecast to Grow at 8.2% CAGR
The Alpha 1 Antitrypsin Deficiency Treatment market in the U.S. is estimated at US$575.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$635 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 7.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.Select Competitors (Total 46 Featured) -
- Abeona Therapeutics Inc.
- Applied Genetic Technologies Corporation
- Arrowhead Pharmaceuticals Inc.
- AstraZeneca PLC
- Baxter International, Inc.
- Biogen, Inc.
- Boehringer Ingelheim International GmbH
- Chiesi Farmaceutici SpA
- CSL Behring
- Curaxys
- GlaxoSmithKline PLC
- Grifols International SA
- Kamada Ltd.
- Pfizer, Inc.
- ProBioGen AG
- ProMetic Life Sciences, Inc.
- Shire PLC
- Teva Pharmaceutical Industries Ltd.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Alpha 1 Antitrypsin Deficiency Treatment?
What is the growth rate of the Global Market for Alpha 1 Antitrypsin Deficiency Treatment?
What is the forecasted size of the Global Market for Alpha 1 Antitrypsin Deficiency Treatment?
Who are the key companies in the Global Market for Alpha 1 Antitrypsin Deficiency Treatment?
Report Attribute | Details |
---|---|
No. of Pages | 196 |
Published | September 2023 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 1.9 Billion |
Forecasted Market Value ( USD | $ 3.8 Billion |
Compound Annual Growth Rate | 9.1% |
Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abeona Therapeutics Inc.
- Applied Genetic Technologies Corporation
- Arrowhead Pharmaceuticals Inc.
- AstraZeneca PLC
- Baxter International, Inc.
- Biogen, Inc.
- Boehringer Ingelheim International GmbH
- Chiesi Farmaceutici SpA
- CSL Behring
- Curaxys
- GlaxoSmithKline PLC
- Grifols International SA
- Kamada Ltd.
- Pfizer, Inc.
- ProBioGen AG
- ProMetic Life Sciences, Inc.
- Shire PLC
- Teva Pharmaceutical Industries Ltd.